Rakovina Therapeutics Announces Publication Highlighting Activity of Novel Bi-functional PARP-HDAC Inhibitor in Preclinical Models of Ewing Sarcoma
14 nov. 2022 09h00 HE
|
Rakovina Therapeutics Inc
Publication to be available on pre-print server, bioRxiv, and will be submitted for scientific journal peer-review VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Rakovina...
Rakovina Therapeutics Announces Preclinical Data Presentation at the 34th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
31 oct. 2022 08h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Announces Upcoming Scientific Conference Presentations
28 sept. 2022 08h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q2 2022 Financial Results and Provides Corporate Update
11 août 2022 15h09 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Results from Annual General Meeting
23 juin 2022 19h07 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update
26 mai 2022 08h30 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Presents Preclinical Data on its Novel kt-3000 Series at the 2022 AACR Special Conference on Sarcomas
11 mai 2022 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update
27 avr. 2022 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 27, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting
12 avr. 2022 09h00 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 12, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas
30 mars 2022 09h16 HE
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, March 30, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company committed to advancing new cancer therapies based...